Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 169 clinical trials
Featured trial
  • 513 views
  • 02 Sep, 2021
  • 1 location
Featured trial
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH). NCT02757768, 178-MA-1008.

lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH). At Screening (Visit 1), subjects will enter into a 4-week open label tamsulosin hydrochloride 0.4 mg QD run-in period

incontinence
tamsulosin
mirabegron
lower urinary tract symptoms
  • 205 views
  • 02 Sep, 2021
  • 1 location
Featured trial
  • 0 views
  • 10 Mar, 2022
  • 1 location
Featured trial
PLUS 1 Study

PLUS 1 Study

  • 249 views
  • 08 Nov, 2020
  • 1 location
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 20 Jun, 2022
  • 1 location
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

deficiency
21-ohd
  • 123 views
  • 27 Apr, 2022
  • 56 locations
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of treatment with crinecerfont. Duration of

classic congenital adrenal hyperplasia
deficiency
21-ohd
  • 0 views
  • 11 Jul, 2022
  • 35 locations
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg tildacerfont QD.

21-ohd
prednisone
17-hydroxyprogesterone
prednisolone
deficiency
  • 28 views
  • 28 Jul, 2022
  • 55 locations
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.

deficiency
prednisolone
21-ohd
prednisone
  • 10 views
  • 25 Jul, 2022
  • 53 locations
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME)

, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21

metabolic syndrome
21-ohd
prednisone
glucocorticoid therapy
glucocorticoids
  • 56 views
  • 14 Apr, 2022
  • 1 location